Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
The dreaded hay fever signs, including itchy eyes, sneezing, and a stuffy nose, have arrived for many people with the arrival of spring. Up to 42% of people experience hay fever, making it a widespread condition. Immune system overreaction is the cause of it.
Read Full NewsResearchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.
Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.
For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.
Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
FDA Greenlights First Engineered Cell Therapy for a Solid Tumor
3.
The FDA Approves the New Frontline Aggressive ALL Regimen.
4.
Studies point to redlining as a 'perfect storm' for breast cancer
5.
Targeted radiation therapy shows near-complete response in rare sarcoma patients
1.
The Power of Salt Tablets: Unlocking Health Benefits Beyond Sodium
2.
Neuroendocrine Tumors: Mechanisms of Mortality, Associated Conditions
3.
Revolutionizing Thyroid Cancer: Advances in Molecular Genetics and Personalized Treatment Approaches
4.
Seeing the Unseen: The Benefits of Early Stage Breast Cancer Ultrasound
5.
Unlocking the Secrets of Follicular Cells: Exploring the Potential of Stem Cell Research
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
International Lung Cancer Congress®
3.
Genito-Urinary Oncology Summit 2026
4.
Future NRG Oncology Meeting
5.
ISMB 2026 (Intelligent Systems for Molecular Biology)
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
3.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge